Research programme: anti-PSCA monoclonal antibodies - Agensys/Merck

Drug Profile

Research programme: anti-PSCA monoclonal antibodies - Agensys/Merck

Latest Information Update: 24 Aug 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Agensys
  • Developer Amgen
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 24 Aug 2011 Discontinued - Preclinical for Cancer in USA (Parenteral)
  • 08 Sep 2008 Preclinical development is ongoing in USA
  • 17 Oct 2005 Agensys and Merck & Co have entered into an agreement to co-develop and co-promote compounds arising from this research programme worldwide for prostate cancer as well as additional cancer indications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top